Teva Pharmaceutical Industries Limited (NYSE:TEVA) is planning to acquire Celltrion, Inc. (KOSDAQ:A068270), people familiar with the matter said. Reports named AstraZeneca PLC (LSE:AZN) and Roche Holding AG (SWX:ROG) as also holding acquisition talks with Celltrion. Celltrion declined to comment on the reports.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
192,500 KRW | +2.01% | +4.22% | -4.47% |
07-01 | S.Korean shares rise on robust data; battery, biopharma stocks jump | RE |
06-17 | Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,343 GBX | +0.81% | +1.98% | 247B | ||
274.8 CHF | +0.31% | +9.04% | 250B | ||
16.38 USD | -1.62% | -3.53% | 18.55B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.47% | 28.7B | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+47.92% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B | |
-5.60% | 11.49B |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Teva Reportedly In Talks To Buy Celltrion